newsfilter
← Latest News
PR Newswire·

Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production

NWBO
  • Northwest Biotherapeutics & the UK National Health Service Blood and Transplant (NHSBT) have entered a collaboration to support production of the experimental cancer vaccine DCVax®-L.
  • NHSBT's Therapeutic Apheresis Services (TAS) will perform leukapheresis procedures to collect immune cell starting material for personalized patient treatments.
  • NHSBT's Cellular and Molecular Therapies (CMT) team will provide specialist cell processing & handling for the manufacturing pathway.
  • The initial collaboration involves NHSBT locations in Leeds & Oxford, with plans to expand the model to additional sites across England.
  • DCVax®-L is a treatment for Glioblastoma multiforme (GBM) & other solid tumors, developed by Northwest Biotherapeutics in partnership with Advent Bioservices.
  • Northwest Biotherapeutics CEO Linda Powers stated the partnership aims to enhance the scale-up & accessibility of DCVax®-L using NHSBT's advanced therapy facilities.
  • Dr. James Griffin, Medical Director at NHSBT, noted the collaboration strengthens UK infrastructure for advanced therapies & explores broader future opportunities.
  • Northwest Biotherapeutics has completed a 331-patient Phase III trial for DCVax®-L in GBM & submitted a Marketing Authorization Application (MAA) to the UK, which is currently under review.
  • The company has also completed a Phase I trial for DCVax®-Direct for inoperable solid tumors & plans to pursue Phase II trials in the current year.